*August 2021*
The CHRYSALIS Study is for adults with previously treated advanced non-small-cell lung cancer (NSCLC). The study is broken down into different parts and is specifically recruiting patients with NSCLC that have a documented primary MET Exon 14 skipping mutation. An investigational medication will be given to eligible participants to assess its the safety, tolerability, and anti-tumor activity.
You may be able to take part in the study if you:
You may be able to take part in the study if you:
- Are 18 years or older
- Have been diagnosed with metastatic or unresectable NSCLC with a documented primary MET Exon 14 skipping mutation
- Must have received prior treatment or declined currently available treatment. There are no limits on lines of prior treatment nor on the type of prior treatment. Patients are eligible post- chemo and post-MET TKI(s).
Contact: JNJ.CT@sylogent.com
Trial Eligibility Criteria and Locations
Trial ID: NCT02609776
Condition: Non-Small Cell Lung Cancer Intervention: Parallel Assignment Study Type: Interventional
Study Phase: I
Study Sponsor: Janssen Research & Development, LLC Trial Start Date: May 24, 2016
Trial End Date: November 1, 2023
Participant Goal: 460
Age Group: 18+ years of age Gender: All
